Dual Antiplatelet Therapy Guidelines

Primary Indications

• The American Heart Association recommends dual antiplatelet therapy (DAPT) for all patients with acute coronary syndrome (ACS) and for all patients undergoing percutaneous coronary intervention (PCI) with stent placement 1, 2
• DAPT is mandatory for all ACS patients regardless of management strategy, including those managed with PCI, medical therapy alone, or coronary artery bypass grafting (CABG) 2, 3
• This includes patients with ST-elevation myocardial infarction (STEMI) - whether managed with primary PCI, delayed PCI, or fibrinolytic therapy 1
• This includes patients with non-ST-elevation myocardial infarction (NSTEMI) 1

Optimal DAPT Regimen

• The American College of Cardiology recommends aspirin 75-100 mg daily PLUS ticagrelor (180 mg loading dose, then 90 mg twice daily) as the first-line regimen for ACS patients 2, 3
• Prasugrel (60 mg loading dose, then 10 mg daily) plus aspirin is an alternative for P2Y12 inhibitor-naïve patients with NSTE-ACS or STEMI undergoing PCI, unless high bleeding risk or contraindications exist 2
• Ticagrelor or prasugrel are strongly preferred over clopidogrel for ACS patients 2, 3

Standard Duration of DAPT

• The default DAPT duration is 12 months for all ACS patients who are not at high bleeding risk, regardless of ACS type, stent type, or completeness of revascularization 1, 2, 3
• For ACS patients treated with fibrinolytic therapy, P2Y12 inhibitor therapy should be continued for a minimum of 14 days and ideally at least 12 months 1
• In ACS patients with high bleeding risk, a shortened DAPT duration of 6 months may be reasonable 1, 2

Bleeding Risk Mitigation Strategies

• Prescribe a proton pump inhibitor (PPI) with DAPT in all patients to reduce gastrointestinal bleeding risk - this is a Class I recommendation 2, 3, 4
• Use radial artery access over femoral access for PCI when performed by an experienced radial operator 2, 3
• Maintain aspirin dose at 75-100 mg daily (not higher doses) when combined with a P2Y12 inhibitor 1, 2

Special Clinical Scenarios

• In ACS patients treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy 1
• Continue aspirin perioperatively if bleeding risk allows 2
• Do not discontinue DAPT within the first month after stent placement for elective non-cardiac surgery - the thrombotic risk is highest in the first month after ACS 2, 4

Critical Pitfalls to Avoid

• Never discontinue DAPT prematurely, especially within the first month after stent placement - this dramatically increases risk of stent thrombosis, myocardial infarction, and death 2, 3, 4
• Never fail to prescribe a PPI with DAPT - this simple intervention significantly reduces gastrointestinal bleeding 2, 3
• Never use clopidogrel as first-line therapy when ticagrelor or prasugrel are available and not contraindicated - this represents suboptimal care for ACS patients 2, 3
• Never administer prasugrel to patients with prior stroke or TIA - this is contraindicated due to increased cerebrovascular bleeding risk 1, 2

Pantoprazole Dosing in High-Risk Cardiovascular Patients

Clinical Context and Indication

• The American College of Physicians and the European Society of Cardiology recommend stress ulcer prophylaxis with a proton pump inhibitor (PPI) for patients at high risk of bleeding, including those on heparin and dual antiplatelet therapy, with a standard dose of pantoprazole 40 mg once daily 5, 6
• For patients with active upper GI bleeding who have undergone endoscopic therapy, twice-daily PPI dosing is recommended after initial high-dose IV therapy, with a reduced rebleeding risk (RR 0.37, 95% CI 0.19-0.73) in high-risk patients (Rockall scores ≥6) 5, 6

Evidence-Based Dosing Algorithm

• The European Society of Cardiology explicitly recommends a PPI in combination with dual antiplatelet therapy as a Class I recommendation to reduce gastrointestinal bleeding risk, with pantoprazole being an appropriate choice due to its low propensity for CYP2C19 inhibition 7, 8, 9
• Pantoprazole has the lowest propensity for CYP2C19 inhibition among PPIs, and studies have found it is not associated with recurrent MI in patients receiving clopidogrel 10, 11

Practical Implementation

• The European Society of Cardiology notes that pantoprazole and rabeprazole have the lowest potential for clinically relevant interactions with clopidogrel, while omeprazole and esomeprazole have the highest propensity 7, 8, 9
• Prescribing pantoprazole 40 mg once daily provides adequate stress ulcer prophylaxis, reduces GI bleeding risk with dual antiplatelet therapy, and minimizes drug-drug interaction concerns 5, 6, 7, 8, 9

Extended Dual Antiplatelet Therapy with Brilinta 60 mg

Patient Selection

• The European Society of Cardiology recommends that patients with a history of myocardial infarction who are at high ischemic risk and have tolerated initial DAPT without bleeding complications may be considered for extended dual antiplatelet therapy with Brilinta 60 mg beyond 12 months 12
• High ischemic risk is defined as age ≥50 years plus at least one additional risk factor: age ≥65 years, diabetes requiring medication, a second prior spontaneous MI, multivessel coronary artery disease, or chronic renal dysfunction (creatinine clearance <60 mL/min) 12

Dosing and Administration

• The American College of Cardiology recommends that for acute coronary syndrome (ACS), ticagrelor 90 mg twice daily (after 180 mg loading dose) is the first-line regimen for the initial 12 months 13, 14, 15, 16, 17
• The European Heart Society recommends that after completing 12 months of DAPT with ticagrelor 90 mg twice daily, continuation with ticagrelor 60 mg twice daily may be preferred over clopidogrel or prasugrel for extended therapy in high-risk MI patients, which represents a Class IIb recommendation (may be considered) 12

Bleeding Risk Mitigation

• The European Society of Cardiology recommends prescribing a proton pump inhibitor (PPI) with any DAPT regimen, which is a Class I recommendation 13, 15, 16, 18
• The American College of Cardiology recommends maintaining aspirin at 75-100 mg daily (not higher doses) when combined with ticagrelor 13, 15, 16, 18

Contraindications

• The European Heart Society recommends that ticagrelor at any dose is contraindicated in patients with previous intracranial hemorrhage or ongoing active bleeding 13, 14, 18

ACC/AHA/SCAI 2025 Guidelines for Ticagrelor Use in Acute Coronary Syndrome

First‑Line Dual Antiplatelet Therapy

• The American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) recommends ticagrelor 180 mg loading followed by 90 mg twice daily plus low‑dose aspirin 75–100 mg daily as the first‑line dual antiplatelet regimen for all adult patients with acute coronary syndrome undergoing percutaneous coronary intervention, irrespective of ST‑elevation status. Class I recommendation. 19

Dosing Regimen

• Loading dose: Give ticagrelor 180 mg as soon as ACS is diagnosed, before any invasive procedure. Class I. 19
• Maintenance dose: Continue ticagrelor 90 mg twice daily for a standard 12‑month period. Class I. 19
• Aspirin dose: Use low‑dose aspirin 75–100 mg daily; higher doses are discouraged. Class I. 19

Preference Over Clopidogrel

• Ticagrelor (or prasugrel) is preferred to clopidogrel for all ACS patients undergoing PCI because it provides a greater reduction in cardiovascular death, myocardial infarction, and stroke. Class I recommendation. 19

Standard Duration of Therapy

• A default DAPT duration of 12 months is advised for all ACS patients who are not at high bleeding risk, regardless of ACS type, stent type, completeness of revascularization, or management strategy (PCI, medical therapy alone, or CABG). Class I. 19

Bleeding‑Risk Mitigation Strategies

• All patients on ticagrelor‑based DAPT should receive a proton‑pump inhibitor to lower gastrointestinal bleeding risk. Class I. 19
• Radial artery access is preferred over femoral access for PCI when performed by an experienced radial operator. Class I. 19

Transition to Ticagrelor Monotherapy

• In patients who have tolerated ticagrelor‑based DAPT without bleeding, discontinuation of aspirin and continuation of ticagrelor alone is recommended at least 1 month after PCI. This strategy reduces bleeding while preserving ischemic protection. Class I. 19

Special Clinical Scenarios

Up‑stream Ticagrelor in NSTEMI

• For non‑ST‑elevation ACS patients whose coronary angiography is delayed beyond 24 hours, early (up‑stream) ticagrelor administration may reduce major adverse cardiovascular events. 19

Patients Requiring Oral Anticoagulation

• Aspirin should be stopped 1–4 weeks after PCI; the P2Y12 inhibitor should be switched from ticagrelor to clopidogrel because clopidogrel carries a substantially lower bleeding risk in triple‑therapy settings. Class I. 19

Contra‑indications & Alternative Agents

• Use clopidogrel instead of ticagrelor in patients with a history of intracranial hemorrhage, those requiring oral anticoagulation (triple therapy), active bleeding, or high bleeding risk who cannot tolerate potent P2Y12 inhibition. Class I. 19
• Use prasugrel instead of ticagrelor in P2Y12‑naïve patients with known coronary anatomy proceeding to PCI, except when age ≥ 75 years, body weight < 60 kg, or prior stroke/TIA are present. Class I. 19

Critical Pitfalls to Avoid

• Do not discontinue dual antiplatelet therapy within the first month after stent placement, as premature cessation markedly increases the risk of stent thrombosis, myocardial infarction, and death. Class I. 19
• Do not omit a proton‑pump inhibitor when prescribing ticagrelor‑based DAPT; omission significantly raises gastrointestinal bleeding risk. Class I. 19
• Do not delay the ticagrelor loading dose; it should be given immediately upon ACS diagnosis, prior to any invasive procedure. Class I. 19
• Do not use high‑dose aspirin (>100 mg) together with ticagrelor; maintain aspirin at 75–100 mg daily to minimize bleeding. Class I. 19

Guideline Recommendations for P2Y12 Inhibitor Use in Acute Coronary Syndrome Undergoing PCI

1. First‑Line P2Y12 Inhibitor: Ticagrelor

• Ticagrelor is the preferred P2Y12 inhibitor for all adult ACS patients undergoing PCI when no contraindications exist, because it lowers major adverse cardiovascular events (MACE), stent thrombosis, and all‑cause mortality compared with clopidogrel. (Class I, ACC/AHA/SCAI guideline) 20
• Loading dose: 180 mg orally administered immediately after ACS diagnosis and before any invasive procedure. (Class I) 20
• Maintenance dose: 90 mg twice daily for a total of 12 months. (Class I) 20
• Aspirin interaction: Concomitant aspirin should be limited to 75–100 mg daily (never >100 mg) because higher aspirin doses diminish ticagrelor’s antiplatelet efficacy. (Class I) 20
• Evidence of mortality benefit: Ticagrelor provides an absolute risk reduction of 1.4 % in 12‑month all‑cause mortality versus clopidogrel (4.5 % vs 5.9 %; P < 0.001). (Class I) 20

2. Second‑Line P2Y12 Inhibitor: Prasugrel

• Prasugrel is an acceptable alternative to ticagrelor for patients who are P2Y12‑inhibitor naïve and whose coronary anatomy is already defined before PCI. (Class I) [21][20]
• Loading dose: 60 mg orally given at the time of PCI (not before coronary anatomy is known). (Class I) [21][22]
• Maintenance dose: 10 mg daily for 12 months. (Class I) [21][22]
• When to choose prasugrel over ticagrelor:
  
  • Ticagrelor is unavailable. (Class I) [21][20]
  • After shared decision‑making, patient preference for prasugrel when efficacy is considered comparable. (Class I) [23][24]
• Absolute contraindication: Prior stroke or transient ischemic attack (TIA) – prasugrel markedly increases cerebrovascular bleeding and worsens net clinical outcomes. (Class III (Harm)) [23][24]20
• Additional cautions (higher bleeding risk): Age ≥ 75 years or body weight < 60 kg. (Class IIa) 20
• Do not administer prasugrel before coronary anatomy is known (Class III). [21][22]

3. Third‑Line P2Y12 Inhibitor: Clopidogrel

• Clopidogrel should be reserved for situations where ticagrelor and prasugrel are unavailable, not tolerated, or contraindicated. (Class I) [21][20]
• Loading dose: 600 mg orally. (Class I) [21][24]
• Maintenance dose: 75 mg daily. (Class I) [21][24]
• Reasons for inferiority: Requires hepatic activation, leading to variable platelet inhibition and a higher risk of MACE and stent thrombosis. (Class IIa) 20
• Clinical scenarios favoring clopidogrel:
  
  • Need for oral anticoagulation (triple therapy) because clopidogrel has a substantially lower bleeding risk in this setting. (Class I) 20
  • History of intracranial hemorrhage. (Class I) 20
  • Active bleeding or a very high bleeding‑risk profile. (Class I) 20

4. Duration of Dual Antiplatelet Therapy (DAPT)

• All ACS patients should receive 12 months of DAPT (aspirin + P2Y12 inhibitor) irrespective of stent type, ACS subtype, or completeness of revascularization. (Class I, European Society of Cardiology) [21][22]20
• High bleeding‑risk patients (PRECISE‑DAPT score ≥ 25) may have DAPT shortened to 6 months. (Class IIa) [21][22]

5. Contraindications & Critical Pitfalls

• Never discontinue DAPT within the first month after stent implantation – early discontinuation markedly raises the risk of stent thrombosis, myocardial infarction, and death. (Class I) 20
• Never give prasugrel to patients with prior stroke or TIA (Class III (Harm)). [23][24]20
• Never use aspirin doses >100 mg daily with ticagrelor – higher doses blunt ticagrelor’s benefit. (Class I) 20
• Never administer prasugrel before coronary anatomy is known (Class III). [21][22]

6. Special Clinical Scenarios

6.1 STEMI Managed with Primary PCI

• Both ticagrelor and prasugrel are recommended over clopidogrel to reduce MACE and stent thrombosis (Class I). [21][20]

6.2 NSTE‑ACS with Delayed Angiography (> 24 h)

• Up‑stream ticagrelor administration may lower MACE when angiography is delayed beyond 24 hours. (Class IIa) 20
• Prasugrel should not be given upstream; it must be administered after coronary anatomy is defined. (Class III) [21][22]

6.3 Patients Requiring Oral Anticoagulation (Triple Therapy)

• Discontinue aspirin 1–4 weeks after PCI and switch the P2Y12 inhibitor from ticagrelor/prasugrel to clopidogrel, because clopidogrel carries a substantially lower bleeding risk in triple‑therapy settings. (Class I) 20

All statements are derived from cited guideline documents and reflect the strength of recommendation (Class I, IIa, III) where provided.

Ticagrelor Contraindications and Safety Considerations

Absolute Contraindications

• Patients with a prior intracranial hemorrhage should not receive ticagrelor because it raises the risk of fatal intracranial bleeding compared with clopidogrel. Class IIa, Level A evidence. 25, 26
• Ticagrelor is contraindicated in anyone with active pathological bleeding (e.g., active gastrointestinal hemorrhage or any life‑threatening bleed). Class I, Level B evidence. 26

Major Bleeding Management

• In the rare event of a life‑threatening bleed while on dual antiplatelet therapy, both antiplatelet agents should be discontinued only if the bleeding cannot be controlled by other measures. Class IIb, Level C evidence. 27
• When a patient has a history of stroke or transient ischemic attack, the increased risk of intracranial bleeding with ticagrelor warrants careful risk‑benefit assessment; clopidogrel may be the safer alternative. Class IIa, Level B evidence. 25

Drug‑Interaction Contraindications

• Concomitant use of ticagrelor with potent CYP3A4 inhibitors (e.g., itraconazole) is contraindicated during the inhibitor course and for up to two weeks after its discontinuation because of markedly elevated ticagrelor plasma levels and heightened bleeding risk. Class I, Level A evidence. 28, 29

Aspirin Dosing Recommendations

• Maintenance aspirin doses exceeding 100 mg daily diminish ticagrelor’s antiplatelet efficacy and should be avoided; this restriction is highlighted in the FDA black‑box warning. Class I, Level A evidence. 29, 28, 27
• The recommended aspirin dose when combined with ticagrelor is 75–100 mg daily (81 mg in the United States). Class I, Level A evidence. 25, 27, 30

Peri‑operative Management

• Ticagrelor should be stopped at least 5 days before any planned surgical procedure to allow adequate recovery of platelet function. Class I, Level A evidence. 25
• Discontinuation of ticagrelor within the first 30 days after stent implantation markedly increases the risk of stent thrombosis, myocardial infarction, and death and should be avoided. Class I, Level A evidence. 27

Special Clinical Situations

• Ticagrelor has not been studied in elective percutaneous coronary intervention (PCI); therefore, no specific guidance exists for its use in that setting. Class III, Level C evidence. 29, 28
• The drug is approved specifically for acute coronary syndrome (ACS) management. Class I, Level A evidence. 27
• Ticagrelor has not been evaluated in patients receiving fibrinolytic therapy; consequently, no recommendations are available for that scenario. Class III, Level C evidence. 29, 28

General Safety Recommendations

• A proton‑pump inhibitor should be prescribed concomitantly with ticagrelor to reduce the risk of gastrointestinal bleeding; this is a Class I recommendation. 27, 30
• Ticagrelor should not be used as part of triple therapy that includes oral anticoagulation and aspirin; in such cases, switching to clopidogrel is advised. Class I, Level A evidence. 30

P2Y12 Inhibitor Selection for ACS Patients with Prior Stroke or TIA

Contraindications

• Prasugrel is absolutely contraindicated in any patient with a prior ischemic stroke or TIA, regardless of how remote the event was (ACC/AHA/SCAI guideline, Class III – Harm). 31
• The prohibition applies to all prior ischemic strokes/TIAs (e.g., events occurring 5, 10, or 20 years ago) with no temporal exemption (ACC/AHA/SCAI and ESC guidance). [31][32]
• Ticagrelor is contraindicated only in patients with a history of intracranial hemorrhage or active bleeding; a prior ischemic stroke or TIA does not preclude its use (ESC guideline, Class I). 33

Preferred P2Y12 Inhibitor

• Ticagrelor is the preferred P2Y12 inhibitor over clopidogrel for ACS patients with a prior stroke/TIA (ACC/AHA/SCAI, Class IIa recommendation). [31][33]

Alternative When Ticagrelor Is Not Feasible

• Clopidogrel (600 mg loading dose, then 75 mg daily) is the default P2Y12 inhibitor when ticagrelor is unavailable, not tolerated, or contraindicated (ACC/AHA/SCAI and ESC, Class I recommendation). [31][33]

Clinical Decision Algorithm

• First‑line therapy: Ticagrelor 180 mg loading dose followed by 90 mg twice daily (demonstrated superior efficacy with similar bleeding to clopidogrel in this subgroup). (ACC/AHA/SCAI). 31
• Second‑line therapy: Clopidogrel 600 mg loading dose then 75 mg daily if ticagrelor cannot be used. (ACC/AHA/SCAI and ESC). [31][33]
• Never use: Prasugrel, due to absolute contraindication irrespective of stroke/TIA timing. (ACC/AHA/SCAI, Class III – Harm). [31][32]

Duration of Dual Antiplatelet Therapy (DAPT)

• Maintain DAPT (aspirin 75–100 mg daily plus the selected P2Y12 inhibitor) for 12 months in patients without high bleeding risk; consider shortening to 6 months only if bleeding risk is elevated (ACC/AHA/SCAI and ESC). [31][33]
• Prescribe a proton‑pump inhibitor to all patients on DAPT (Class I recommendation). (ESC). 33

Evidence Basis

• The TRITON‑TIMI 38 trial showed that prasugrel increased cerebrovascular bleeding and worsened net clinical outcomes in patients with prior stroke/TIA, leading to a FDA black‑box warning and Class III – Harm recommendation across major guidelines (ACC/AHA/SCAI, ESC). [31][32]
• The 2021 ACC/AHA/SCAI guideline and the 2020 ESC guideline both state that a prior ischemic stroke/TIA is not a contraindication to ticagrelor, but is a contraindication to prasugrel. (ACC/AHA/SCAI, ESC). [31][33]

Common Pitfalls to Avoid

• Do not assume that a remote stroke (>5 years) makes prasugrel acceptable; the contraindication has no temporal limitation (ACC/AHA/SCAI, ESC). [31][32]
• Do not discontinue DAPT within the first 30 days after stent placement, as early discontinuation markedly increases stent thrombosis risk (ACC/AHA/SCAI). 31

Ticagrelor as First‑Line P2Y12 Inhibitor for ACS Patients Undergoing PCI

First‑Line Therapy Recommendations

• The European Society of Cardiology (ESC) and the European Association for Cardio‑Thoracic Surgery (EACTS) 2019 guidelines give a Class I recommendation that ticagrelor (180 mg loading, then 90 mg twice daily) be used instead of clopidogrel for all acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). 34
• Ticagrelor combined with low‑dose aspirin (75–100 mg daily) for 12 months is the preferred dual antiplatelet therapy (DAPT) regimen in this population. 35
• Ticagrelor reduces major adverse cardiovascular events, stent thrombosis, and all‑cause mortality compared with clopidogrel in ACS after PCI. 34

Loading and Maintenance Dosing

• Administer a 180 mg oral loading dose of ticagrelor immediately after ACS diagnosis and before any invasive procedure. 35
• Continue ticagrelor 90 mg twice daily for a total of 12 months. 34
• Aspirin should be given at 75–100 mg daily; doses >100 mg blunt ticagrelor’s antiplatelet effect. 35

Situations Favoring Clopidogrel

• Clopidogrel (600 mg loading, then 75 mg daily) is reserved for patients in whom ticagrelor is contraindicated or not tolerated. 36
• When oral anticoagulation is required (triple therapy), clopidogrel provides a substantially lower bleeding risk than ticagrelor (Class I recommendation by the 2018 North American consensus). 37
• In patients with active bleeding or a very high bleeding risk, clopidogrel’s less potent platelet inhibition results in fewer bleeding events. 38

Prasugrel as an Alternative

• Prasugrel (60 mg loading, then 10 mg daily) is an acceptable alternative P2Y12 inhibitor for P2Y12‑naïve patients proceeding to PCI. 34
• Absolute contraindication: Prasugrel must not be used in patients with a prior stroke or transient ischemic attack (Class III Harm). 35
• Relative contraindications (higher bleeding risk): age ≥ 75 years or body weight < 60 kg. 34

Duration of Dual Antiplatelet Therapy

• Standard DAPT duration is 12 months for all ACS patients after PCI, irrespective of stent type or ACS subtype (Class I). 36
• In patients with a high bleeding risk (PRECISE‑DAPT score ≥ 25), shortening DAPT to 6 months may be considered. 35

Bleeding‑Risk Mitigation Strategies

• All patients on DAPT should receive a proton‑pump inhibitor (PPI) – Class I recommendation to reduce gastrointestinal bleeding. 34
• Radial artery access for PCI should be used when performed by an experienced radial operator to lower bleeding complications. 36
• Maintain aspirin at 75–100 mg daily; higher doses increase bleeding without improving efficacy. 35

Practical Implementation Algorithm

• At ACS diagnosis, load with ticagrelor 180 mg plus aspirin 150–300 mg (loading dose), then continue ticagrelor 90 mg twice daily, aspirin 75–100 mg daily, and a PPI for 12 months. 34
• If any of the following are present, switch to clopidogrel:
  
  • Requirement for oral anticoagulation (triple therapy) – lower bleeding risk with clopidogrel. 37
  • Active bleeding or very high bleeding risk – clopidogrel associated with fewer bleeding events. 38
• If considering prasugrel:
  
  • Prior stroke/TIA → avoid prasugrel; use ticagrelor. 35
  • Age ≥ 75 years or weight < 60 kg → prefer ticagrelor over prasugrel. 34

Critical Pitfalls to Avoid

• Never discontinue DAPT within the first month after stent placement, as this markedly raises the risk of stent thrombosis, myocardial infarction, and death. 35
• Never omit a PPI when prescribing DAPT; doing so significantly increases gastrointestinal bleeding. 34
• Never use prasugrel in patients with a prior stroke or TIA (absolute contraindication). 35
• Never use clopidogrel as first‑line therapy when ticagrelor is available and not contraindicated; doing so represents suboptimal care for ACS patients. 34

Prasugrel Use in Acute Coronary Syndrome: Indications, Timing, and Contraindications

Indications

• Prasugrel is FDA‑approved to reduce thrombotic cardiovascular events in patients with unstable angina or non‑ST‑elevation myocardial infarction (NSTEMI) who are planned for percutaneous coronary intervention (PCI). [European Society of Cardiology (ESC) guideline, Class IIa] 39

Timing Requirement (Coronary Anatomy Must Be Known)

• The drug must be given only after diagnostic coronary angiography has defined the coronary anatomy and confirmed that PCI will be performed; the loading dose may be administered before, during, or within 1 hour after PCI. [ESC guideline, Class III recommendation against earlier use] 39, 40
• Class III recommendation: Prasugrel should not be administered before coronary anatomy is known. 41

Contraindications & Situations to Avoid

• Prasugrel has not been studied and is not recommended for ACS patients managed medically without PCI. [ESC guideline] 41, 39, 40
• Absolute contraindication: prior stroke or transient ischemic attack. 42, 43
• Avoid in patients likely to require urgent coronary artery bypass grafting (CABG); prasugrel must be stopped ≥ 7 days before surgery. 41

Dosing and Treatment Duration (When Indicated)

• After coronary anatomy is known and PCI is planned, give a 60 mg loading dose of prasugrel. 39, 40
• Continue prasugrel 10 mg daily for 12 months. 42

Comparison with Ticagrelor

• Ticagrelor is the preferred first‑line P2Y12 inhibitor for all ACS presentations because it can be administered immediately upon diagnosis, before angiography, and is effective regardless of whether the patient undergoes PCI, medical therapy, or CABG. [ESC guideline] 41
• If upstream P2Y12 inhibition is desired (i.e., before angiography), ticagrelor 180 mg loading dose should be used instead of prasugrel. 41

Guideline Recommendations (ESC 2020)

• The 2020 ESC guidelines recommend against pre‑treatment with prasugrel in NSTE‑ACS patients before angiography, citing the ACCOAST trial, which showed no ischemic benefit and a substantially higher bleeding risk. [Class III] 41
• For NSTE‑ACS patients who proceed to PCI after coronary anatomy is known, prasugrel is considered the preferred P2Y12 inhibitor. [Class IIa] 41

Switching from Prasugrel to Alternative P2Y12 Inhibitors in Patients with Dyspnea

Indications for Switching

• When a patient develops new or worsening shortness of breath after initiating prasugrel, transition to clopidogrel 75 mg daily (with a 600 mg loading dose if not previously loaded) or ticagrelor 90 mg twice daily (with a 180 mg loading dose). 44

Clopidogrel as First‑Line Alternative

• The ACC/AHA recommends clopidogrel as the preferred substitute when prasugrel must be stopped for any reason, including suspected adverse effects. [44][45]
• Loading dose: 600 mg orally once. [45][46]
• Maintenance dose: 75 mg orally daily. [45][46]
• Therapy duration: Continue for 12 months after an acute coronary syndrome (ACS) unless the patient has a high bleeding risk, in which case a minimum of 6 months is acceptable. [44][45]
• Aspirin co‑therapy: Maintain low‑dose aspirin 75–100 mg daily alongside clopidogrel. [44][45]
• Efficacy‑safety trade‑off: Compared with prasugrel, clopidogrel yields a modest absolute increase of ≈2–3 % in major adverse cardiovascular events (MACE) over 12 months, but it markedly reduces major bleeding risk. [44][45]

Ticagrelor as Second‑Line Alternative

• Ticagrelor is an acceptable option when clopidogrel is unavailable or when clinicians wish to preserve potent platelet inhibition. 44
• Loading dose: 180 mg orally once. 44
• Maintenance dose: 90 mg orally twice daily. 44
• Therapy duration: 12 months post‑ACS. 44
• Aspirin co‑therapy: Low‑dose aspirin 75–100 mg daily; doses >100 mg should be avoided because they diminish ticagrelor’s antiplatelet effect. 44
• Dyspnea risk: Ticagrelor is associated with dyspnea in 14–39 % of patients (versus 7–9 % with clopidogrel), typically emerging within the first week; the symptom is usually mild, self‑limited, and rarely necessitates drug discontinuation. 44

Contraindications & Safety Alerts

• Prasugrel: Absolutely contraindicated in anyone with a prior stroke or transient ischemic attack (TIA); such patients must be switched to clopidogrel or ticagrelor regardless of dyspnea status. [44][45]46
• Ticagrelor: Contraindicated in patients with a history of intracranial hemorrhage or active bleeding. 44
• Dual Antiplatelet Therapy (DAPT) interruption: Do not discontinue DAPT within the first 30 days after stent implantation without interventional cardiology consultation, as early cessation dramatically raises the risk of stent thrombosis, myocardial infarction, and death. 44

Bleeding‑Risk Mitigation

• The ACC/AHA gives a Class I recommendation to prescribe a proton‑pump inhibitor (PPI) to all patients receiving DAPT. 44
• Pantoprazole 40 mg daily is preferred because it has the lowest potential for CYP2C19 inhibition and does not attenuate clopidogrel’s antiplatelet activity. 47

Ticagrelor (Brilinta) Dosing and Management After PCI

Standard Dosing Regimen

• Loading dose: Give 180 mg ticagrelor orally as soon as possible after acute coronary syndrome (ACS) diagnosis and before any invasive procedure; platelet inhibition is achieved within ~30 minutes. 48
• Maintenance dose: Continue 90 mg ticagrelor twice daily for at least 12 months after PCI, irrespective of stent type (drug‑eluting or bare‑metal) or ACS subtype. 48
• Aspirin co‑therapy: Combine ticagrelor with low‑dose aspirin 75–100 mg daily; doses >100 mg blunt ticagrelor’s antiplatelet effect (FDA black‑box warning). 48

Special Population Adjustments

• Elderly (≥75 years): No dose reduction; standard 90 mg twice‑daily regimen is recommended. 48
• Low body weight (≤60 kg): No dose adjustment needed for ticagrelor, unlike prasugrel which requires a reduced dose. 49
• Moderate renal impairment (CKD stage ≥3b): Standard ticagrelor dosing is appropriate; no adjustment required. 48

Duration of Dual Antiplatelet Therapy (DAPT)

• Standard duration: Maintain DAPT (ticagrelor + aspirin) for 12 months in all ACS patients post‑PCI who are not at high bleeding risk, regardless of stent type or completeness of revascularization. 48
• High bleeding risk: Consider shortening DAPT to 6 months when the PRECISE‑DAPT score is ≥25, balancing ischemic and bleeding risks. 48

Bleeding‑Risk Mitigation Strategies

• Proton‑pump inhibitor (PPI): Prescribe a PPI to every patient on DAPT (Class I recommendation) to lower gastrointestinal bleeding risk. 48
• Radial access: Prefer radial artery access over femoral for PCI when performed by an experienced radial operator, reducing access‑site bleeding. 48

Peri‑operative Management

• Early postoperative period: Do not discontinue DAPT within the first 30 days after stent placement for elective non‑cardiac surgery; early cessation markedly raises the risk of stent thrombosis, myocardial infarction, and death. 50

Common Pitfalls to Avoid

• Aspirin dose: Never exceed 100 mg daily of aspirin when combined with ticagrelor, as higher doses diminish ticagrelor efficacy. 50
• Premature DAPT interruption: Avoid stopping DAPT early, especially within the first month after stent implantation, because this substantially increases stent thrombosis risk. 50
• PPI omission: Do not omit a PPI when prescribing DAPT; its use significantly reduces gastrointestinal bleeding. 48
• Loading‑dose delay: Administer the ticagrelor loading dose immediately upon ACS diagnosis, before any invasive procedure, to ensure rapid platelet inhibition. 50
• Assumed dose adjustments: Do not assume ticagrelor requires dose modification for age, body weight, or renal function; standard dosing applies across these groups (unlike prasugrel). 48

Management of Antiplatelet Therapy and Bleeding Risk in Acute Coronary Syndrome with Low Hemoglobin

Bleeding Risk Associated with Dual Antiplatelet Therapy

• In patients with acute coronary syndrome receiving dual antiplatelet therapy (aspirin + a P2Y12 inhibitor), the bleeding risk is substantially higher than with aspirin monotherapy; reducing therapy to aspirin alone provides a more favorable balance between ischemic protection and bleeding complications. 51

Choice of P2Y12 Inhibitor to Discontinue

• Ticagrelor and prasugrel produce more rapid and potent platelet inhibition than clopidogrel, which is associated with a higher incidence of major bleeding events; therefore, these agents should be the first to be held when bleeding necessitates de‑escalation of therapy. 51

Timing of Resumption of P2Y12 Inhibition

• After hemostasis is achieved, the P2Y12 inhibitor should be restarted promptly to complete the guideline‑recommended 12‑month duration of dual antiplatelet therapy. 51

Gastro‑Protective Strategy (Class I Recommendation)

• All patients on dual antiplatelet therapy should receive a proton‑pump inhibitor (e.g., pantoprazole 40 mg daily) to lower the risk of gastrointestinal bleeding. This recommendation carries Class I evidence strength. 51

Aspirin Dose Optimization

• When combined with a P2Y12 inhibitor, aspirin should be administered at a low dose of 75–100 mg daily; higher doses do not provide additional antithrombotic benefit and increase bleeding risk. 51

Vascular Access Technique for PCI

• Radial artery access, performed by an experienced radial operator, should be preferred over femoral access for percutaneous coronary intervention to reduce access‑site bleeding complications. 51

Dual Antiplatelet Therapy (DAPT) Guidelines for Acute Coronary Syndrome (ACS) and Percutaneous Coronary Intervention (PCI)

1. P2Y12 Inhibitor Selection

• The American College of Cardiology (ACC) recommends ticagrelor as the preferred P2Y12 inhibitor over clopidogrel for all ACS patients undergoing PCI because it lowers major adverse cardiovascular events, stent thrombosis, and all‑cause mortality. 52
• The American Heart Association (AHA) classifies prior ischemic stroke or transient ischemic attack (TIA) as an absolute contraindication to prasugrel (Class III, Harm). 53

2. Standard DAPT Duration

• ACC guidance states that a 12‑month DAPT course is the default for all ACS patients without high bleeding risk, irrespective of ACS subtype (STEMI, NSTEMI, unstable angina), stent type (drug‑eluting or bare‑metal), or completeness of revascularisation. [54][55]53
• For patients with stable coronary artery disease undergoing PCI, ACC recommends a 6‑month DAPT duration regardless of stent type. 54
• In ACS patients identified as high bleeding risk (PRECISE‑DAPT score ≥ 25), ACC suggests that a shortened 6‑month DAPT regimen may be reasonable. 53

3. Bleeding‑Risk Mitigation Strategies

• ACC advises using radial artery access rather than femoral access for PCI when performed by an experienced radial operator to reduce bleeding and vascular complications. 52
• AHA recommends maintaining aspirin at 75–100 mg daily (and not exceeding 100 mg) when combined with any P2Y12 inhibitor to preserve antiplatelet efficacy. 53

4. Management Around Coronary Artery Bypass Grafting (CABG)

• AHA advises that, after CABG, the P2Y12 inhibitor component of DAPT should be resumed so that the patient completes a total of 12 months of therapy. 53
• ACC recommends discontinuing ticagrelor or clopidogrel at least 5 days before an elective CABG. 55
• ACC recommends discontinuing prasugrel at least 7 days before an elective CABG. 55

5. Transition to P2Y12‑Inhibitor Monotherapy

• ACC states that, in patients who have tolerated DAPT without bleeding, stopping aspirin after 1–3 months while continuing the P2Y12 inhibitor as monotherapy is reasonable to lower bleeding risk. 52
• This approach has been shown to reduce bleeding events while maintaining ischemic protection. 52

Alternative P2Y12 Inhibitor Strategies When Ticagrelor Is Unavailable

Drug Selection and Dosing Regimens

• Prasugrel is the preferred first‑line alternative to ticagrelor for ACS patients undergoing PCI – give a 60 mg oral loading dose after coronary anatomy is known, followed by 10 mg daily for 12 months. (Class I recommendation) 56
• Clopidogrel is the preferred alternative for all ACS patients not undergoing PCI – give a 600 mg oral loading dose, then 75 mg daily for 12 months. (Class I recommendation) 57
• For STEMI managed with fibrinolysis, clopidogrel should be used exclusively – give a 300 mg loading dose in patients ≤75 years old (75 mg if >75 years), then 75 mg daily. (Class I recommendation) 56

Contra‑indications and Dose Adjustments

• Absolute contraindication to prasugrel: any prior stroke or transient ischemic attack, which raises cerebrovascular bleeding risk (≈6.5 % vs 1.2 % with clopidogrel) and worsens net clinical outcomes. (Class III) 57
• Relative contraindication: body weight < 60 kg – consider a reduced prasugrel maintenance dose of 5 mg daily because of higher bleeding risk. (Class IIa) 56

Adjunctive Therapy

• All patients on dual antiplatelet therapy (DAPT) must receive low‑dose aspirin (75–100 mg daily, never >100 mg). (Class I) 57
• A proton‑pump inhibitor (PPI) is required for all DAPT patients to lower gastrointestinal bleeding risk. (Class I) 56

Standard Duration of Dual Antiplatelet Therapy

• Twelve months of DAPT is mandatory for every ACS patient, irrespective of ACS subtype, stent type, or management strategy (PCI, CABG, or medical therapy). (Class I) 57
• Exception: patients with high bleeding risk (PRECISE‑DAPT score ≥ 25) may have DAPT shortened to 6 months. (Class IIb) 56

Timing of P2Y12 Inhibitor Administration

• Prasugrel must not be administered before coronary anatomy is known; give the loading dose only after diagnostic angiography confirms that PCI will be performed. (Class III) 57
• Clopidogrel may be given immediately at ACS diagnosis, before angiography, providing flexibility for both invasive and non‑invasive pathways. (Class I) 56

Comparative Efficacy and Safety

• Clopidogrel is less potent than ticagrelor or prasugrel, leading to a modest absolute increase in 12‑month MACE (≈2–3 %) but offering substantially lower bleeding risk, making it the preferred agent for high‑bleeding‑risk patients. (Class IIa) 57
• Prasugrel delivers rapid, consistent platelet inhibition and reduces major adverse cardiovascular events (MACE) and stent thrombosis to a degree comparable with ticagrelor in PCI patients. (Class I) 56

Clinical Pitfalls to Avoid

• Do not discontinue DAPT within the first 30 days after stent placement – early discontinuation markedly raises the risk of stent thrombosis, myocardial infarction, and death. (Class III) 57
• Never give prasugrel to patients with a prior stroke/TIA – this is an absolute contraindication regardless of how remote the event was. (Class III) 56
• Never administer prasugrel before coronary anatomy is defined – wait for angiographic confirmation of PCI. (Class III) 57
• Never omit a PPI when prescribing DAPT – PPIs significantly reduce gastrointestinal bleeding. (Class I) 56
• Never exceed 100 mg daily aspirin dose with any P2Y12 inhibitor – higher aspirin doses increase bleeding without added antiplatelet benefit. (Class III) 57
• Never use prasugrel for medically managed ACS without PCI – it is contraindicated and lacks proven benefit in this setting. (Class III) 56

Triple‑Therapy (Oral Anticoagulation) Considerations

• When oral anticoagulation is required, switch to clopidogrel (continue anticoagulant, discontinue aspirin 1–4 weeks after PCI). Clopidogrel provides a markedly lower bleeding risk in triple‑therapy regimens. (Class IIa) 56

Dual Antiplatelet Therapy (DAPT) Guidelines for Coronary Artery Disease

1. Indications & Standard Duration

• All patients with acute coronary syndrome (ACS) and all patients undergoing percutaneous coronary intervention (PCI) with stent placement should receive DAPT (aspirin 75–100 mg daily + a P2Y12 inhibitor) for 12 months, unless a high bleeding risk requires shortening to 6 months (Class I, strong evidence)【58】.
• For ACS (STEMI, NSTEMI, unstable angina), the standard DAPT duration is 12 months regardless of stent type, ACS subtype, or management strategy (PCI, medical therapy, or CABG) (Class I)【58】【59】【60】.
• If a patient has a high bleeding risk (PRECISE‑DAPT score ≥ 25), DAPT should be shortened to 6 months (Class I)【58】【59】【60】.
• Extended DAPT (>12 months) may be considered in patients who tolerate therapy without bleeding and have a high ischemic risk (Class IIb)【58】【59】.

2. P2Y12 Inhibitor Selection

First‑Line: Ticagrelor

• Ticagrelor (180 mg loading, then 90 mg twice daily) is the preferred P2Y12 inhibitor for all ACS patients, irrespective of whether they undergo PCI, medical management, or coronary artery bypass grafting (CABG) (Class I)【58】.

Second‑Line: Prasugrel

• Prasugrel (60 mg loading, then 10 mg daily) is acceptable for P2Y12‑naïve patients proceeding to PCI, but only after coronary anatomy has been defined (Class I)【58】.
• Prasugrel must not be given before angiography confirms that PCI will be performed (Class I)【59】.
• Prior stroke or transient ischemic attack at any time is an absolute contraindication to prasugrel (Class III Harm)【58】.

Third‑Line: Clopidogrel

• Clopidogrel (600 mg loading, then 75 mg daily) should be used only when ticagrelor and prasugrel are unavailable, not tolerated, or contraindicated (Class I)【58】.

3. DAPT Duration by Clinical Scenario

4. Bleeding‑Risk Mitigation Strategies (Class I)

• Prescribe a proton‑pump inhibitor (PPI) to every patient on DAPT; this markedly reduces gastrointestinal bleeding【58】【60】.
• Maintain aspirin dose at 75–100 mg daily (81 mg in the United States) and never exceed 100 mg when combined with any P2Y12 inhibitor【58】.
• Use radial artery access rather than femoral access for PCI when performed by an experienced radial operator; this lowers bleeding and vascular complications【58】.

5. Special Clinical Scenarios

Triple Therapy (DAPT + Oral Anticoagulation)

• Limit triple‑therapy duration to a maximum of 6 months (or omit after hospital discharge) to balance ischemic protection against bleeding risk (Class IIa)【60】.

Peri‑operative Management for Non‑Cardiac Surgery

• Do not discontinue DAPT within the first 30 days after stent placement for elective non‑cardiac surgery; early cessation dramatically increases stent thrombosis, myocardial infarction, and death (Class I)【60】.

Transition to P2Y12‑Inhibitor Monotherapy

• In patients who have tolerated DAPT without bleeding, aspirin may be stopped after 1–3 months and the P2Y12 inhibitor continued as monotherapy, reducing bleeding while preserving ischemic protection (Class IIa)【58】.

6. Critical Pitfalls to Avoid (Class I)

• Never omit a PPI when prescribing DAPT – omission significantly raises gastrointestinal bleeding risk【58】.
• Never administer prasugrel to patients with a prior stroke or TIA – absolute contraindication regardless of timing【58】.
• Never give prasugrel before coronary anatomy is known – wait for angiographic confirmation of PCI【59】.

All statements are derived from guideline‑level evidence (Class I–III) as cited.